Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Martin
S Eric
SE
Sausen
Mark
M
Joseph
Abraham
A
Kingham
Brewster F
BF
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D000069439:Dasatinib; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics; D013844:Thiazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib